Precision Acupuncture in the Treatment of Peripheral Neuropathy After Taxanes Chemotherapy in Breast Cancer

Inclusion Criteria: 1. The patient was at least 18 years old and had reported grade 1 or higher neuropathic symptoms for more than 2 weeks; 2. Patients were screened for eligibility by the investigator prior to enrollment, including verification of baseline neuropathic symptoms. 3. Patients had a diagnosis of stage I, II, or IIIA breast cancer; 4. Have completed at least 2 weeks of chemotherapy; 5. Higher scores indicate more severe symptoms; 6. Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent); 7. Eastern Cooperative Oncology Group (ECOG ) score of physical condition (0-1); 8. Patients with previous local recurrence were eligible; 9. The basic indexes were consistent, and the blood routine and ECG were normal. Exclusion Criteria: 1. patients with needle phobia; 2. Low platelet count (\<50 000); co-morbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels \<10 g/dl and haematocrit \<30; anaemia on active pharmacological treatment or receiving blood transfusion or steroids; 3. having metastatic or recurrent disease, history of preexisting peripheral neuropa- thy prior to chemotherapy, uncontrolled seizure disorder, unstable cardiac disease or myocardial infarction within 6 months prior to study entry; 4. Being pregnant or nursing, or having used acupuncture for peripheral neuropathy within 6 months prior to study entry; 5. Life expectancy \<6 months; 6. Lymphedema of limbs;